A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

The first report to compare what pharmaceutical companies are doing to bring antimicrobial resistance under control. By highlighting innovative actions, it encourages more companies to seize opportunities for change.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • In the media
  • Despite looming resistance crisis, Novartis d...
Media - published on 12 Jul 2018

Despite looming resistance crisis, Novartis ducks out of antibiotics research

Phil Taylor of FierceBiotech reports on Novartis’ recent announcement to shut down its antibacterial and antiviral research programmes. The article refers to the findings of the Foundation’s AMR Benchmark, published in January 2018.

“According to a recent report by the Access to Medicine Foundation (AMF), the multinational pharma companies’ retreat from the sector is a problem. While companies like GlaxoSmithKline, Johnson & Johnson and Pfizer are leading the charge, there is still not enough being done on an industrywide basis to avert a future healthcare crisis."

Learn more

View our detailed overview of each company’s performance in the Index, including breakdowns of their product portfolios and R&D pipelines.